Chua V - Search Results

1

The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).

Chua V, Mattei J, Han A, Johnston L, LiPira K, Selig SM, Carvajal RD, Aplin AE, Patel SP. Chua V, et al. Clin Cancer Res. 2021 Jan 1;27(1):28-33. doi: 10.1158/1078-0432.CCR-20-2536. Epub 2020 Oct 15. Clin Cancer Res. 2021. PMID: 33060121 Free PMC article.

2

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE. Cheng H, et al. Among authors: chua v. Mol Cancer Ther. 2017 Mar;16(3):516-528. doi: 10.1158/1535-7163.MCT-16-0552. Epub 2017 Jan 30. Mol Cancer Ther. 2017. PMID: 28138035 Free PMC article.

3

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.

Chua V, Lapadula D, Randolph C, Benovic JL, Wedegaertner PB, Aplin AE. Chua V, et al. Mol Cancer Res. 2017 May;15(5):501-506. doi: 10.1158/1541-7786.MCR-17-0007. Epub 2017 Feb 21. Mol Cancer Res. 2017. PMID: 28223438 Free PMC article. Review.

4

Novel therapeutic strategies and targets in advanced uveal melanoma.

Chua V, Aplin AE. Chua V, et al. Curr Opin Oncol. 2018 Mar;30(2):134-141. doi: 10.1097/CCO.0000000000000425. Curr Opin Oncol. 2018. PMID: 29206651 Review.

5

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.

Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Chua V, et al. EMBO Mol Med. 2019 Feb;11(2):e9081. doi: 10.15252/emmm.201809081. EMBO Mol Med. 2019. PMID: 30610113 Free PMC article.

6

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK. Ambrosini G, et al. Among authors: chua v. Cancer Res. 2019 May 1;79(9):2415-2425. doi: 10.1158/0008-5472.CAN-18-3177. Epub 2019 Mar 18. Cancer Res. 2019. PMID: 30885979 Free PMC article.

7

Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.

Teh JLF, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso J, Aplin AE. Teh JLF, et al. Among authors: chua v. Mol Cancer Ther. 2020 Aug;19(8):1719-1726. doi: 10.1158/1535-7163.MCT-19-1016. Epub 2020 May 19. Mol Cancer Ther. 2020. PMID: 32430489 Free PMC article.

8

BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.

Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, Harbour JW, Aplin AE. Han A, et al. Among authors: chua v. Oncogene. 2021 Jan;40(3):618-632. doi: 10.1038/s41388-020-01554-y. Epub 2020 Nov 18. Oncogene. 2021. PMID: 33208912 Free PMC article.

9

Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.

Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, Harbour JW, Aplin AE. Han A, et al. Among authors: chua v. Oncogene. 2021 Mar;40(9):1753. doi: 10.1038/s41388-021-01645-4. Oncogene. 2021. PMID: 33510355 Free PMC article. No abstract available.

10

The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.

Chua V, Han A, Bechtel N, Purwin TJ, Hunter E, Liao C, Harbour JW, Aplin AE. Chua V, et al. Pigment Cell Melanoma Res. 2022 Jan;35(1):78-87. doi: 10.1111/pcmr.13007. Epub 2021 Aug 12. Pigment Cell Melanoma Res. 2022. PMID: 34347929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters